Robert Blaustein's most recent trade in Edgewise Therapeutics Inc was a trade of 105,000 Stock Options (Right to buy) done . Disclosure was reported to the exchange on Aug. 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Edgewise Therapeutics Inc | Robert Blaustein | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2025 | 105,000 | 105,000 | - | - | Stock Options (Right to buy) | |
| Edgewise Therapeutics Inc | Robert Blaustein | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2025 | 17,500 | 17,500 | - | - | Restricted Stock Units | |
| Edgewise Therapeutics Inc | Robert Blaustein | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2025 | 160,000 | 160,000 | - | - | Stock Options (Right to buy) | |
| Edgewise Therapeutics Inc | Robert Blaustein | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2025 | 30,000 | 30,000 | - | - | Restricted Stock Units |